Iboxamycin

Iboxamycin is a synthetic lincosamide or oxepanoprolinamide antibiotic. It binds to the bacterial ribosome in both Gram-negative and Gram-positive bacteria and it has been found to effective against bacteria which are resistant to other antibiotics that target the large ribosomal subunit. It was developed by combining an oxepanoproline unit with the aminooctose residue of clindamycin.

Iboxamycin has been found to be effective against ESKAPE bacteria, methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus, Clostridium difficile, and Listeria monocytogenes, indicating an extended spectrum when compared to clindamycin. Isotopic labeling of iboxamycin with tritium indicated that it binds 70 times more tightly to the ribosome than clindamycin.

Iboxamycin can be administered orally and has been found to be safe when administered to mice. It is a bacteriostatic antibiotic.